H.R. 10857: Faster Clinical Trials Act
The bill would create and expand several FDA programs aimed at speeding up medical research, improving how clinical trials are run, and strengthening oversight of drug development and labeling.
Clinical Trials and Research Infrastructure
The bill would establish an FDA-led Cures in Care program to make it easier to run routine clinical trials within ordinary health care settings. It would encourage the use of decentralized methods, including digital and AI-enabled tools, and would place priority on sites that serve underserved populations. The program would include lead trial networks, a public-private collaboration effort, training, reporting requirements, and new grant funding. It would authorize $500 million per year from 2027 through 2031.
The bill would also require more standardized and interoperable data sharing for these point-of-care trials. It would expand FDA and CMS guidance on how trials are paid for, allow privacy-protected data linkage, and update oversight rules for trial conduct. It would also modernize review of early-stage trials, support alignment with international standards, and require closer scrutiny of foreign data used in FDA decisions.
Rare Disease Support
The bill would create an FDA Rare Disease Innovation Hub to help speed rare disease trials, biomarker development, and collaboration with nontraditional sponsors. The hub would receive funding, form partnerships, and submit reports on its activities and progress.
Drug Review and Manufacturing Oversight
The bill would make several FDA process changes intended to reduce delays and improve review efficiency. These changes would address clinical holds, generic drug review, biosimilar review, and inspection processes. It would also update certain procedures related to early-phase clinical research and foreign-source data used in regulatory review.
Oncology and Genomic Labeling
The bill would establish an Oncology Center of Excellence and create a new FDA process for reviewing genomic exclusion labeling for cancer drugs. The FDA would identify oncology drugs that may need genomic exclusion warnings, set standards for those labels, encourage voluntary label updates, and provide expedited review. It would also require public reporting, issue guidance, and send reports to Congress. The bill would define the criteria for this process while preserving FDA authority over labeling decisions.
Relevant Companies
- ILMN — Illumina may be affected by expanded use of genomic information in drug labeling and oncology review, since its sequencing technologies are widely used in clinical and cancer testing workflows.
- TMO — Thermo Fisher Scientific could be affected by increased clinical trial activity, diagnostic testing, and research infrastructure spending, including work tied to decentralized trials and biomarker development.
- DHR — Danaher may be indirectly affected through its life sciences and diagnostics businesses if the bill increases clinical research, biomarker testing, and rare disease development activity.
- ABT — Abbott could be affected through diagnostic and clinical testing products used in trials, rare disease work, and oncology-related testing.
- RHHBY — Roche may be impacted by faster oncology review processes and genomic labeling changes, since it has a large cancer drug portfolio and diagnostics business.
- AMGN — Amgen could be affected by changes in biosimilar review, oncology oversight, and FDA review processes relevant to biologic drug development.
- REGN — Regeneron may be affected by changes in clinical trial policy, genomic labeling, and oncology-related FDA review practices.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
3 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Oct. 22, 2026 | Introduced in House |
| Oct. 22, 2026 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.